← FDA DRUG APPROVALS
FDA ANDA · ANDA204627
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Sponsor: PADAGIS US
APPLICATION
ANDA204627
TYPE
ANDA
ORIGINAL APPROVAL
2014-04-29
LATEST ACTION
2025-04-09
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued
Products
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDEDiscontinued
CHLORPHENIRAMINE MALEATE 4MG/5ML, HYDROCODONE BITARTRATE 5MG/5ML, PSEUDOEPHEDRINE HYDROCHLORIDE 60MG/5ML · SOLUTION · ORAL
Approval history
2025-04-09Labeling · Supplement 5 · standardAP
2023-12-15Labeling · Supplement 4 · standardAP
2023-10-18Labeling · Supplement 2 · standardAP
2023-10-18Labeling · Supplement 3 · standardAP
2014-04-29UNKNOWN · OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.